抗体药物偶联物：癌症治疗与成像的设计与开发，法国图尔，2017 年 7 月 27-28 日，LabEx MAbImprove 工业研讨会。
Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France.
机构信息
a Equipe 4 IMT GICC, Université François Rabelais , Tours , France.
b Equipe 1 FRAME GICC, Université François Rabelais , Tours , France.
出版信息
MAbs. 2018 Feb/Mar;10(2):210-221. doi: 10.1080/19420862.2017.1412130. Epub 2018 Jan 9.
Abstract
The annual "Antibody Industrial Symposium", co organized by LabEx MAbImprove, MabDesign and Polepharma, was held in Tours, France on June 27-28, 2017. The focus was on antibody-drug-conjugates (ADCs), new entities which realize the hope of Paul Ehrlich's magic bullet. ADCs result from the bioconjugation of a highly cytotoxic drug to a selective monoclonal antibody, which acts as a vector. Building on knowledge gained during the development of three approved ADCs, brentuximab vedotin (Adcetris®), ado trastuzumab emtansine (Kadcyla®) and inotuzumab ozogamicin (Besponsa®), and the many ADCs in development, this meeting addressed strategies and the latest innovations in the field from fundamental research to manufacturing.
摘要
2017 年 6 月 27 日至 28 日，法国图尔举办了由 LabEx MAbImprove、MabDesign 和 Polepharma 共同组织的年度“抗体工业研讨会”。会议重点关注抗体药物偶联物（ADC），这是一种新型实体药物，实现了保罗·埃尔利希（Paul Ehrlich）“魔术子弹”的期望。ADC 是通过将高细胞毒性药物与选择性单克隆抗体进行生物偶联而制成的，该抗体可作为载体。基于在三种已批准的 ADC（brentuximab vedotin，Adcetris®；ado trastuzumab emtansine，Kadcyla®；inotuzumab ozogamicin，Besponsa®）和许多正在开发中的 ADC 的研发过程中所获得的知识，本次会议从基础研究到制造，探讨了该领域的策略和最新创新。
相似文献
1
Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France.抗体药物偶联物：癌症治疗与成像的设计与开发，法国图尔，2017 年 7 月 27-28 日，LabEx MAbImprove 工业研讨会。
MAbs. 2018 Feb/Mar;10(2):210-221. doi: 10.1080/19420862.2017.1412130. Epub 2018 Jan 9.
2
Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index.抗体药物偶联物：改善治疗指数的临床和转化策略的未来方向。
Clin Cancer Res. 2019 Sep 15;25(18):5441-5448. doi: 10.1158/1078-0432.CCR-19-0272. Epub 2019 Apr 12.
3
Recent advances of antibody drug conjugates for clinical applications.抗体药物偶联物在临床应用中的最新进展。
Acta Pharm Sin B. 2020 Sep;10(9):1589-1600. doi: 10.1016/j.apsb.2020.04.012. Epub 2020 Apr 24.
4
Antibody-drug conjugates: present and future.抗体偶联药物：现状与未来。
MAbs. 2014 Jan-Feb;6(1):15-7. doi: 10.4161/mabs.27436.
5
Current methods for the synthesis of homogeneous antibody-drug conjugates.目前用于合成均相抗体药物偶联物的方法。
Biotechnol Adv. 2015 Nov 1;33(6 Pt 1):775-84. doi: 10.1016/j.biotechadv.2015.05.001. Epub 2015 May 14.
6
Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.抗体药物偶联物：临床药学对一种新兴癌症治疗方法的观点
Pharmacotherapy. 2016 Jan;36(1):99-116. doi: 10.1002/phar.1687.
7
World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany.世界抗体药物偶联物峰会欧洲会议：2011 年 2 月 21 日-23 日；德国法兰克福。
MAbs. 2011 Jul-Aug;3(4):331-7. doi: 10.4161/mabs.3.4.16612. Epub 2011 Jul 1.
8
Site-specific antibody drug conjugates for cancer therapy.用于癌症治疗的靶向抗体药物偶联物。
MAbs. 2014 Jan-Feb;6(1):34-45. doi: 10.4161/mabs.27022.
9
Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany.第四届世界抗体药物偶联物峰会：2012 年 2 月 29 日-3 月 1 日，德国法兰克福。
MAbs. 2012 Nov-Dec;4(6):637-47. doi: 10.4161/mabs.21697. Epub 2012 Aug 22.
10
Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.药物-抗体比例对抗体-美登素类偶联物药代动力学、生物分布、疗效和耐受性的影响
Bioconjug Chem. 2017 May 17;28(5):1371-1381. doi: 10.1021/acs.bioconjchem.7b00062. Epub 2017 Apr 13.
引用本文的文献
1
Optimization of Adcitmer, a Monomethyl-Auristatin E bearing antibody-drug conjugate for the treatment of CD56-expressing cancers.Adcitmer（一种携带单甲基奥瑞他汀E的抗体药物偶联物）用于治疗表达CD56的癌症的优化。
J Immunother Cancer. 2025 Mar 13;13(3):e010897. doi: 10.1136/jitc-2024-010897.
2
Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study.实体癌中抗体药物偶联物相关出版物的研究趋势：一项文献计量学研究
Front Pharmacol. 2022 Jun 20;13:921385. doi: 10.3389/fphar.2022.921385. eCollection 2022.
3
Recent advances in the development of active hybrid molecules in the treatment of cardiovascular diseases.用于治疗心血管疾病的活性杂合分子开发的最新进展。
Bioorg Med Chem. 2022 May 15;62:116706. doi: 10.1016/j.bmc.2022.116706. Epub 2022 Mar 11.
4
Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity.蛋白酶激活 Fc 掩蔽治疗性抗体以减轻肿瘤外细胞毒性。
Front Immunol. 2021 Aug 3;12:715719. doi: 10.3389/fimmu.2021.715719. eCollection 2021.
5
Novel single-domain antibodies against the EGFR domain III epitope exhibit the anti-tumor effect.针对表皮生长因子受体（EGFR）结构域III表位的新型单域抗体具有抗肿瘤作用。
J Transl Med. 2020 Oct 6;18(1):376. doi: 10.1186/s12967-020-02538-y.
6
Antibody-Drug Conjugates: The Last Decade.抗体药物偶联物：过去十年
Pharmaceuticals (Basel). 2020 Sep 14;13(9):245. doi: 10.3390/ph13090245.
7
Quantification of an Antibody-Conjugated Drug in Fat Plasma by an Affinity Capture LC-MS/MS Method for a Novel Prenyl Transferase-Mediated Site-Specific Antibody-Drug Conjugate.新型法尼基转移酶介导的定点抗体药物偶联物中结合物在脂肪血浆中的定量分析：一种亲和捕获 LC-MS/MS 方法
Molecules. 2020 Mar 26;25(7):1515. doi: 10.3390/molecules25071515.
8
Pharmacokinetic and Metabolism Studies of Monomethyl Auristatin F via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry.通过液质联用技术研究单甲基澳瑞他汀 F 的药代动力学和代谢。
Molecules. 2019 Jul 29;24(15):2754. doi: 10.3390/molecules24152754.
9
Targeting the Tetraspanins with Monoclonal Antibodies in Oncology: Focus on Tspan8/Co-029.肿瘤学中用单克隆抗体靶向四跨膜蛋白：聚焦于Tspan8/Co-029
Cancers (Basel). 2019 Feb 3;11(2):179. doi: 10.3390/cancers11020179.
10
DNA damaging agent-based antibody-drug conjugates for cancer therapy.用于癌症治疗的基于DNA损伤剂的抗体药物偶联物。
Antib Ther. 2018 Sep;1(2):33-43. doi: 10.1093/abt/tby007. Epub 2018 Aug 30.
本文引用的文献
1
Nanofitin as a New Molecular-Imaging Agent for the Diagnosis of Epidermal Growth Factor Receptor Over-Expressing Tumors.纳米适配体作为一种新型分子成像剂用于诊断表皮生长因子受体过表达肿瘤
Bioconjug Chem. 2017 Sep 20;28(9):2361-2371. doi: 10.1021/acs.bioconjchem.7b00374. Epub 2017 Sep 12.
2
Regiospecific radiolabelling of Nanofitin on Ni magnetic beads with [F]FBEM and in vivo PET studies.用[F]FBEM对镍磁珠上的纳米适配体进行区域特异性放射性标记及体内PET研究。
Nucl Med Biol. 2017 Aug;51:33-39. doi: 10.1016/j.nucmedbio.2017.04.006. Epub 2017 Apr 27.
3
Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3.神经调节蛋白 1 变构增强非竞争抗 HER3 抗体 9F7-F11 的抗肿瘤作用，增加其与 HER3 的结合。
Mol Cancer Ther. 2017 Jul;16(7):1312-1323. doi: 10.1158/1535-7163.MCT-16-0886. Epub 2017 May 15.
4
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.塞古图珠单抗阿穆纳白介素（CEA-IL2v），一种用于联合癌症免疫治疗的基于癌胚抗原（CEA）靶向白介素-2变体的免疫细胞因子：克服阿地白介素和传统基于白介素-2的免疫细胞因子的局限性。
Oncoimmunology. 2017 Jan 11;6(3):e1277306. doi: 10.1080/2162402X.2016.1277306. eCollection 2017.
5
Strategies and challenges for the next generation of antibody-drug conjugates.下一代抗体药物偶联物的策略与挑战。
Nat Rev Drug Discov. 2017 May;16(5):315-337. doi: 10.1038/nrd.2016.268. Epub 2017 Mar 17.
6
Highly Potent, Anthracycline-based Antibody-Drug Conjugates Generated by Enzymatic, Site-specific Conjugation.通过酶促位点特异性偶联产生的高效蒽环类抗体药物偶联物
Mol Cancer Ther. 2017 May;16(5):879-892. doi: 10.1158/1535-7163.MCT-16-0688. Epub 2017 Mar 3.
7
Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion.利用半胱氨酸插入法高效制备位点特异性抗体-药物偶联物
Mol Pharm. 2017 May 1;14(5):1501-1516. doi: 10.1021/acs.molpharmaceut.6b00995. Epub 2017 Mar 16.
8
Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates.用于抗体药物偶联物的聚乙二醇化葡糖醛酸 - 单甲基澳瑞他汀E连接子的优化
Mol Cancer Ther. 2017 Jan;16(1):116-123. doi: 10.1158/1535-7163.MCT-16-0343. Epub 2016 Nov 9.
9
Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload.临床抗体药物偶联物吡咯并苯二氮䓬二聚体有效载荷替西瑞林的设计与合成。
ACS Med Chem Lett. 2016 May 24;7(11):983-987. doi: 10.1021/acsmedchemlett.6b00062. eCollection 2016 Nov 10.
10
Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize.抗微管药物与抗 ErbB 抗体偶联可选择性放射增敏。
Nat Commun. 2016 Oct 4;7:13019. doi: 10.1038/ncomms13019.
Zotero 插件